These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16928822)

  • 1. Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy.
    Hoffmann D; Wildner O
    Mol Cancer Ther; 2006 Aug; 5(8):2013-22. PubMed ID: 16928822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
    Hoffmann D; Bangen JM; Bayer W; Wildner O
    Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy.
    Hoffmann D; Grunwald T; Kuate S; Wildner O
    Cancer Biol Ther; 2007 Apr; 6(4):510-8. PubMed ID: 17374986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
    Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
    Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
    Mato-Berciano A; Raimondi G; Maliandi MV; Alemany R; Montoliu L; Fillat C
    Oncotarget; 2017 Apr; 8(14):22700-22715. PubMed ID: 28186974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment.
    Hoffmann D; Wildner O
    Mol Cancer Ther; 2006 Feb; 5(2):374-81. PubMed ID: 16505112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines.
    Hoffmann D; Bayer W; Wildner O
    World J Gastroenterol; 2007 Jun; 13(22):3063-70. PubMed ID: 17589921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.
    Jung KH; Choi IK; Lee HS; Yan HH; Son MK; Ahn HM; Hong J; Yun CO; Hong SS
    Cancer Lett; 2017 Jun; 396():155-166. PubMed ID: 28315430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
    Halloran CM; Ghaneh P; Shore S; Greenhalf W; Zumstein L; Wilson D; Neoptolemos JP; Costello E
    J Gene Med; 2004 May; 6(5):514-25. PubMed ID: 15133762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.
    Onimaru M; Ohuchida K; Nagai E; Mizumoto K; Egami T; Cui L; Sato N; Uchino J; Takayama K; Hashizume M; Tanaka M
    Cancer Lett; 2010 Aug; 294(2):178-86. PubMed ID: 20163915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.
    Hoffmann D; Bayer W; Wildner O
    Hum Gene Ther; 2007 May; 18(5):435-50. PubMed ID: 17518612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter.
    Jacob D; Davis JJ; Zhang L; Zhu H; Teraishi F; Fang B
    Cancer Gene Ther; 2005 Feb; 12(2):109-15. PubMed ID: 15486557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
    Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.
    Maliandi MV; Mato-Berciano A; Sobrevals L; Roué G; José A; Fillat C
    Mol Cancer; 2015 Jul; 14():146. PubMed ID: 26227809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in oncolytic adenovirus therapy for pancreatic cancer.
    Nattress CB; Halldén G
    Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer.
    Uchida D; Shiraha H; Kato H; Nagahara T; Iwamuro M; Kataoka J; Horiguchi S; Watanabe M; Takaki A; Nouso K; Nasu Y; Yagi T; Kumon H; Yamamoto K
    J Gastroenterol Hepatol; 2014 May; 29(5):973-83. PubMed ID: 24372695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
    Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
    Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.
    Eisenberg DP; Adusumilli PS; Hendershott KJ; Yu Z; Mullerad M; Chan MK; Chou TC; Fong Y
    J Gastrointest Surg; 2005 Nov; 9(8):1068-77; discussion 1077-9. PubMed ID: 16269377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.
    Chen HH; Cawood R; El-Sherbini Y; Purdie L; Bazan-Peregrino M; Seymour LW; Carlisle RC
    Mol Ther; 2011 Jan; 19(1):67-75. PubMed ID: 20877345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.